Yes, Harvoni tablets are not considered a controlled substance in the UK, but you should carry a copy of your prescription and a letter from your clinician if you are traveling to countries with strict medication import rules.
St. John’s wort induces enzymes that can lower Harvoni concentrations, potentially reducing effectiveness. It is advisable to avoid this supplement during treatment or discuss alternatives with your pharmacist.
Both Harvoni (ledipasvir/sofosbuvir) and Epclusa (sofosbuvir/velpatasvir) contain sofosbuvir, but they differ in the second component. Epclusa is approved for all HCV genotypes, whereas Harvoni is primarily used for genotypes 1, 4, 5, and 6. Choice depends on genotype, prior treatment history, and specialist recommendation.
Take the missed tablet as soon as you remember, provided it is the same day. If you realise the omission the next day, skip the missed dose and continue with the regular schedule; do not double-dose.
Patients with eGFR ≥ 30 mL/min/1.73 m² can use Harvoni without dose adjustment. Those with more severe renal dysfunction require specialist assessment before starting therapy.
Antacids containing aluminium or magnesium may reduce absorption if taken within two hours of the Harvoni tablet. Separate administration by at least two hours is recommended.
SVR12 confirms that the virus has been eradicated. A negative result at 12 weeks after therapy is considered a cure and guides long-term follow-up planning.
There are no specific dietary restrictions. However, maintaining a balanced diet supports liver health during treatment.
Do not use Harvoni beyond the printed expiry date. Potency cannot be guaranteed after this point, and the medication should be disposed of safely.
Harvoni is not known to cause false-positive results in standard drug-of-abuse screens, but athletes subject to anti-doping testing should disclose all prescribed medications to the relevant authority.
Harvoni combines the active ingredients ledipasvir and sofosbuvir in a single oral tablet (90 mg / 400 mg). It belongs to the antiviral class of medicines and is approved in the United Kingdom for the treatment of chronic hepatitis C virus (HCV) infection. The medication is supplied as a film-coated pill and is prescribed only by a qualified healthcare professional.
Regulatory status: Prescription-only medicine (POM) authorized by the Medicines and Healthcare products Regulatory Agency (MHRA).
Manufacturer: Gilead Sciences Ltd. (UK subsidiary).
Harvoni’s antiviral effect stems from the complementary actions of its two components:
Together, the drugs achieve a rapid decline in circulating HCV RNA, typically within the first two weeks of therapy. The combination provides a high barrier to resistance and allows a once-daily dosing schedule.
Harvoni is approved in the UK for the following HCV-related indications:
These approvals are based on clinical trials demonstrating sustained virologic response at 12 weeks after treatment (SVR12) rates of >95 % in most patient groups. The medication is indicated for adults (≥ 18 years) and is not recommended for use in children unless specifically authorised in a clinical trial.
Evidence from small studies suggests possible benefit of ledipasvir/sofosbuvir in:
Disclaimer: These uses are not approved by the MHRA. Off-label prescribing must be performed under specialist supervision, with individual risk assessment.
Ideal candidates are adults with chronic HCV genotype 1, 4, 5, or 6 infection, who have adequate renal function (eGFR ≥ 30 mL/min/1.73 m²) and no contraindicated concomitant medications.
These events are usually mild and transient, often improving without intervention.
| Interaction Type | Representative Drugs | Clinical Significance | ||-|--| | Major | Amiodarone, dronedarone | May cause serious bradycardia; avoid co-administration. | | Moderate | Rifampin, carbamazepine, phenytoin, St. John’s wort | Induce enzymes that reduce Harvoni exposure; dose adjustment or alternative therapy required. | | Moderate | HIV protease inhibitors boosted with ritonavir, atazanavir, lopinavir/ritonavir | May increase ledipasvir concentrations; monitor for toxicity. | | Minor | Antacids containing aluminium or magnesium | May reduce absorption if taken within 2 hours of the tablet; separate administration recommended. |
If a patient is taking other medicines, a pharmacist should review the full list for potential interactions.
This article provides educational information about Harvoni and is not a substitute for professional medical advice. Treatment decisions, including the use of unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes only and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
